Imagery Interventions and Cognitive-Behavioural Therapy for Psychological Complaints Related to Bullying: A Systematic Review and Meta-Analysis.

Clin Psychol PsychotherJan 1, 2026
Clinical ResearchPsychiatryOpen access

Meng Liang, Gerly Tamm, Olivia De Laere et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed individual cognitive-behavioural therapy (CBT) and imagery interventions for bullying victims, examining internalizing symptoms, self-perception and coping. Across 23 studies, unadjusted pre–post analyses found reduced internalizing symptoms (k = 21, g = 0.72), but after adjustment for publication bias the effect was smaller and no longer statistically significant (g = 0.26). Adjusted improvement in self-perception and coping was g = 0.98. Internalizing symptom improvements at follow-up remained significant after adjustment (g = 0.37). The authors note substantial heterogeneity and methodological limitations.

Key findings

  • Unadjusted pre–post internalizing symptoms decreased (k = 21, g = 0.72); after publication-bias adjustment, the effect was g = 0.26 and no longer statistically significant.
  • At follow-up, the adjusted internalizing symptom effect was g = 0.37 and remained significant.
  • After publication-bias adjustment, the effect on self-perception and coping was g = 0.98.
  • Heterogeneity was substantial across outcomes (I 2 = 68%-98%).

Why it matters

The findings suggest that CBT and imagery interventions may help address psychological difficulties following bullying, but estimated benefits depend on outcome and adjustment for publication bias. The contrast between internalizing symptoms and self-perception or coping underscores the need to assess outcomes separately. High heterogeneity and methodological limitations mean pooled estimates should be interpreted cautiously.

What to keep in mind

The review reports substantial heterogeneity, methodological limitations and publication bias; the adjusted pre–post internalizing effect was no longer statistically significant.

Source

Published in Clin Psychol Psychother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.